title: Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.
abstract: OBJECTIVE
  The use of a potent combination of antiretroviral (ARV) drugs, so-called highly active ARV therapy (HAART), has dramatically improved the quality of life and overall survival of children with human immunodeficiency virus (HIV) infection. However, these benefits can be compromised by the development of drug resistance. Our objectives were to analyze the prevalence and pattern of HIV-drug resistance among HIV-infected children failing first-line HAART.
  
  
  METHODS
  Retrospective study based on data obtained from July 2006 through January 2009 of prevalence of genotypic resistance estimated in HAART-treated children who experienced virologic failure (HIV RNA > 1000 copies/mL) at a tertiary care center in Riyadh.
  
  
  METHODS
  The characteristics of the study population and genotype resistance data were analyzed in ARV-treated children who experience virologic failure.
  
  
  RESULTS
  Among 22 children who underwent resistance testing, the prevalence of resistance to any drug was 86.4%. Inadequate adherence to ARVs in children with drug resistance was 91%. Twenty-four mutations were detected within the protease coding region and 14 in the reverse transcriptase (RT) coding region. In 80% of isolates piM36I was detected, while rtM184V was detected in 70% of the isolates and was associated with cross-resistance to at least two nucleoside RT inhibitors (NRTI). Clinically significant non-nucleoside RT inhibitors (NNRTI) resistance was conferred by rtK103N. The best ARV susceptibility was to lopinavir in the PI class. ARV resistance was not associated with geographic regions or the CDC classification status. Study children responded satisfactorily to genotype-guided treatment and intensive family counseling.
  
  
  CONCLUSIONS
  ARVs resistance is common among HIV-infected Saudi children who experienced virologic failure to HAART. Inadequate adherence is a common cause for resistance to ARVs in children. Mutations M36I and M184V were more frequent for PIs, NRTIs and NNRTIs. Evaluation of genotype tests should be considered in all children with therapeutic failure to guide future selection of ARV regimens. These data will help improve clinical management of HIV-infected children in Saudi Arabia.
authors: Pediatric Infectious Diseases, King Faisal Specialist Hospital and Research Centre, Riyadh 11211 SaudiArabia. hajjar@kfshrc.edu.sa
authors: Sami Hussain
authors: SH
authors: Al Hajjar
authors: Husn
authors: H
authors: Frayha
authors: Sahar
authors: S
authors: Althawadi
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D002648:Child; D004252:DNA Mutational Analysis; D004279:DNA, Viral / Q000235:genetics*; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008297:Male; D009154:Mutation; D015995:Prevalence; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D012529:Saudi Arabia / Q000453:epidemiology; D017211:Treatment Failure; D019562:Viral Load
chemical_list: D004279:DNA, Viral; D018894:Reverse Transcriptase Inhibitors
references: J Clin Microbiol. 2002 Dec;40(12):4512-9
references: 12454144
references: N Engl J Med. 2004 Mar 4;350(10):1023-35
references: 14999114
references: J Med Virol. 2007 Sep;79(9):1261-9
references: 17607781
references: BMC Pediatr. 2008 Sep 04;8:34
references: 18771599
references: Pediatr Infect Dis J. 2003 Jan;22(1):56-62
references: 12544410
references: J Med Virol. 2002 Nov;68(3):299-304
references: 12226814
references: Mem Inst Oswaldo Cruz. 2003 Sep;98(6):831-7
references: 14595464
references: AIDS. 2003 Nov 7;17(16):2383-8
references: 14571191
references: J Infect Dis. 2003 Aug 15;188(4):537-40
references: 12898440
references: Expert Rev Anti Infect Ther. 2007 Feb;5(1):13-28
references: 17266450
references: J Infect Dis. 2000 Feb;181(2):729-32
references: 10669364
references: AIDS. 2004 Jan 23;18(2):237-45
references: 15075541
references: Pediatr Infect Dis J. 2000 Apr;19(4):363-4
references: 10783035
references: J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):44-50
references: 21099693
references: Pediatr Infect Dis J. 2001 Dec;20(12):1174-6
references: 11740328
references: AIDS. 2004 Jul 2;18(10):1393-401
references: 15199315
references: Clin Infect Dis. 2001 Mar 1;32(5):774-82
references: 11229846
references: J Virol. 2001 Jun;75(11):4999-5008
references: 11333879
references: Pediatrics. 2002 Apr;109(4):e61
references: 11927734
references: AIDS Res Hum Retroviruses. 2011 Sep;27(9):945-56
references: 21345162
references: AIDS. 1999 Sep 10;13(13):1705-9
references: 10509572
references: Pediatr Infect Dis J. 2008 Aug;27(8):749-52
references: 18664987
references: Adv Pharmacol. 2008;56:121-67
references: 18086411
references: J Clin Virol. 2004 May;30(1):24-31
references: 15072750
references: J Med Virol. 1999 Dec;59(4):507-11
references: 10534734